Galmed Pharmaceuticals Secures $10M Equity Agreement
Company Announcements

Galmed Pharmaceuticals Secures $10M Equity Agreement

Galmed Pharmaceuticals (GLMD) has released an update.

Galmed Pharmaceuticals Ltd., an Israeli company, has entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing Galmed to issue and sell up to $10 million of its ordinary shares to the investor. These shares are traded on the Nasdaq Capital Market under the symbol ‘GLMD’ and will be sold pursuant to exemption rules of the Securities Act of 1933. This strategic financial move aims to enhance Galmed’s capital position, providing a flexible way to access funds.

For further insights into GLMD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGalmed Pharmaceuticals Amends Equity Purchase Agreement
TheFlyGalmed files to sell 1M shares of common stock for holders
TipRanks Auto-Generated NewsdeskGalmed Reports Breakthrough in MASH Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App